Last $13.29 USD
Change Today +0.19 / 1.45%
Volume 14.8M
BSX On Other Exchanges
New York
As of 8:04 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

boston scientific corp (BSX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/22/14 - $14.08
52 Week Low
07/12/13 - $9.38
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BOSTON SCIENTIFIC CORP (BSX)

boston scientific corp (BSX) Related Businessweek News

View More BusinessWeek News

boston scientific corp (BSX) Details

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products used to treat patients with atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to treat patients with peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat patients with non-vascular disease. In addition, it offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable pacemaker systems, including implantable cardiac resynchronization therapy pacemaker to treat heart failure; and medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart comprising radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, the company provides endoscopy products to treat diseases of the digestive and pulmonary systems; stone management products to treat patients with urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products; and devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs. Boston Scientific Corporation was founded in 1979 and is headquartered in Natick, Massachusetts.

23,000 Employees
Last Reported Date: 02/26/14
Founded in 1979

boston scientific corp (BSX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $900.0K
Executive Vice President of Global Operations...
Total Annual Compensation: $517.7K
Executive Vice President and President of Asi...
Total Annual Compensation: $537.3K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $612.0K
Compensation as of Fiscal Year 2013.

boston scientific corp (BSX) Key Developments

Boston Scientific Corporation Announces Results from Parkinson's Disease Study

Boston Scientific Corporation has announced encouraging results from VANTAGE, a prospective, multi-center trial evaluating the Vercise deep brain stimulation, or DBS, system in patients with Parkinson's disease, or PD. VANTAGE is a prospective, multi-center trial evaluating the Vercise DBS System assessing patient outcomes in PD, including effectiveness, safety and health economic data. Forty patients with PD were treated with the Vercise DBS System at six European centers. The VANTAGE study reported a 62% improvement in motor function at 12 months post implant, as assessed by the UPDRS III scale, when compared to baseline. This result is consistent with the six month interim data presented last year, demonstrating that patients benefitted from therapy over time. In addition, patients reduced medication usage by 58% at 12 months compared to their usage prior to the DBS procedure.

Clinical Study Results Demonstrate Therapeutic Advantages of the Boston Scientific Vercise DBS System for Patients with Parkinson's Disease

A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific Vercise Deep Brain Stimulation (DBS) System for the treatment of Parkinson's disease (PD). The CUSTOM-DBS clinical study demonstrated that shorter stimulation pulses may offer a clinical advantage over DBS therapy using conventional pulses. The Vercise DBS System is the only commercially available platform with the capability to generate stimulation pulses at the shorter pulse width settings. The Boston Scientific CUSTOM-DBS study is a randomized, multi-center, double-blind trial evaluating clinical advantages of the Vercise DBS System for patients with PD. Fifteen patients previously implanted with the Boston Scientific Vercise DBS System were programmed and assessed using test and control pulse widths. The study demonstrated that DBS stimulation with shorter pulses results in larger therapeutic windows that may be advantageous for avoiding stimulation-related side effects. The therapeutic window is the range of electrical currents that provides effective therapy without causing side effects. In CUSTOM-DBS, patients' DBS implants were stimulated with brief electrical pulses that were shorter than conventional settings. To compare the two settings, efficacy of the stimulation was evaluated using the standard UPDRS III score assessment for PD, and thresholds for achieving efficacy and side effects were measured. The comparisons were randomized and double-blinded, making this one of the first studies to provide Level I evidence of a clinical advantage to specific deep brain stimulation settings, such as shorter pulse widths. The Vercise DBS System is the first DBS system with multiple independent current control technology designed for accurate neural targeting and precise control of the stimulation therapy for patients with PD. DBS is a surgical treatment that can help reduce some PD symptoms. It involves the placement of a device that stimulates specific areas of the brain using electrical signals. DBS is typically used to treat people with advanced PD whose symptoms are no longer controlled by medication. PD is a progressive neurological disorder which affects 6.3 million people worldwide. Boston Scientific is an innovation leader in implantable DBS technology. The Vercise DBS System has both CE Mark and TGA (Australia Therapeutic Goods Administration) approval and is available for sale in Europe, Israel, Australia and select countries in Latin America for PD, and CE Mark approval for intractable primary and secondary dystonia.

Boston Scientific Corporation Reports Strong Performance Data for SYNERGY(TM) Stent System

Boston Scientific Corporation reported positive three-year follow-up data for the EVOLVE clinical trial, comparing the safety and performance of the SYNERGY(TM) Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium (PtCr) Coronary Stent System to the PROMUS Element(TM) Stent System. The data were presented on May 21, 2014 at EuroPCR 2014 by Professor Ian Meredith, director of MonashHeart, at Monash Medical Centre in Melbourne, Australia. The primary clinical and angiographic endpoints of this non-inferiority study have already been published. Boston Scientific has expanded its commercial launch of the SYNERGY Stent System in Europe and in select markets in Asia. It features an ultrathin abluminal bioabsorbable drug/polymer coating technology which eliminates long-term polymer exposure. In addition to reducing restenosis, the SYNERGY Stent System may also offer faster and more complete vessel healing after stent implantation, potentially reducing the duration of post-procedure dual antiplatelet therapy. The SYNERGY Stent System is supported by a rigorous clinical program. Beyond the EVOLVE Study three-year results, the EVOLVE II Clinical Trial, which completed enrollment in August 2013, is the pivotal trial designed to support U.S. Food and Drug Administration and Japanese Ministry of Health, Labor and Welfare approval of the SYNERGY Stent System. EVOLVE II is a global, multicenter, randomized, controlled pivotal trial that enrolled 1,684 patients in 125 sites worldwide, including the U.S., Canada, Europe, Australia, New Zealand, Japan and Singapore. Additional studies to assess outcomes, including the potential for reduced dual antiplatelet therapy, will be supported by Boston Scientific. The SYNERGY Stent System is being investigated in multiple independent, real-world studies across the spectrum of cardiovascular disease complexity.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:US $13.29 USD +0.19

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $119.36 USD +0.49
Olympus Corp ¥3,625 JPY +5.00
Smith & Nephew PLC 1,020 GBp +3.00
St Jude Medical Inc $70.07 USD +1.06
Zimmer Holdings Inc $103.79 USD +0.12
View Industry Companies

Industry Analysis


Industry Average

Valuation BSX Industry Range
Price/Earnings 48.7x
Price/Sales 2.5x
Price/Book 2.7x
Price/Cash Flow 22.5x
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at